文献速递心境障碍

成人急性躁狂药物治疗的疗效、安全性与耐受性比较:随机对照试验的系统综述与网络荟萃分析

Comparative efficacy, safety, and tolerability of pharmacotherapies for acute mania in adults: a systematic review and network meta-analysis of randomized controlled trials.
PubMed 文献 · Mol Psychiatry · 2024-08-27

该系统综述与网络荟萃分析纳入113项随机对照试验、23491名成人急性双相躁狂患者,比较51种单药、辅助治疗或安慰剂。他莫昔芬及他莫昔芬联合锂盐/丙戊酸盐的临床疗效优于安慰剂,奥氮平、帕利哌酮、喹硫平、齐拉西酮、利培酮、双丙戊酸盐和氟哌啶醇的耐受性显著优于安慰剂,抗精神病药联合锂盐/丙戊酸盐似乎比相应单药更有效。

要点

  • 他莫昔芬(平均差-22.31)和他莫昔芬联合锂盐/丙戊酸盐(-16.37)的疗效优于安慰剂。
  • 奥氮平、帕利哌酮、喹硫平、齐拉西酮、利培酮、双丙戊酸盐和氟哌啶醇的耐受性显著优于安慰剂。
  • 抗精神病药联合锂盐/丙戊酸盐似乎比相应单药更有效。

核心结论

  • 他莫昔芬和他莫昔芬联合锂盐/丙戊酸盐在成人急性双相躁狂中疗效优于安慰剂,分别位列第一和第二。
  • 奥氮平、帕利哌酮、喹硫平、齐拉西酮、利培酮、双丙戊酸盐和氟哌啶醇的耐受性显著优于安慰剂。
  • 抗精神病药联合锂盐/丙戊酸盐似乎比相应单药更有效。
  • 与安慰剂相比,未发现头痛或抑郁事件发生率增加的证据。

研究设计与样本

  • 系统综述与网络荟萃分析,使用R软件及相关程序包。
  • 检索主要临床数据库至2023年2月,纳入成人急性双相躁狂药物治疗及辅助治疗的随机对照试验。
  • 共纳入113项研究,23491名参与者(男性50.38%;平均年龄38.6岁;平均研究时长3.39周;平均躁狂基线评分29.37),随机分配至51种单药、辅助治疗或安慰剂。

主要发现

  • 奥氮平、帕利哌酮、喹硫平、齐拉西酮、利培酮、双丙戊酸盐和氟哌啶醇的耐受性显著优于安慰剂。
  • 抗精神病药联合锂盐/丙戊酸盐似乎比相应单药更有效。
  • 与安慰剂相比,未发现头痛或抑郁事件发生率增加的证据。

关键数值与推荐

  • 疗效结局:躁狂评分从基线至终点的平均变化。
  • 安全性结局:从基线至治疗结束的临床显著不良事件。
  • 耐受性结局:完成整个试验至计划终点的患者比例。

临床怎么用

  • 该网络荟萃分析可为临床医生治疗急性双相躁狂的决策提供参考。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The aim of this study was to provide evidence-based recommendations regarding the efficacy, safety, and tolerability of currently used pharmacological treatments for adults with acute bipolar mania. To achieve this, we conducted a systematic review and network meta-analysis (NMA) using R software and related packages. We searched primary clinical databases until February 2023 for reports of randomized controlled trials of drug treatments and adjunctive therapies for adults with acute bipolar mania, with outcomes including efficacy (mean change from baseline to endpoint in mania rating scores), safety (clinically significant adverse events from baseline to end of treatment), and tolerability (the proportion of patients who completed the whole trial to the planned endpoint). A total of 113 studies were included in our analysis, in which 23,491 participants (50.38% males; mean age = 38.6 years; mean study duration = 3.39 weeks; mean manic baseline score = 29.37) were randomly allocated to one of 51 monotherapies, adjunctive treatments, or placebo. Our results showed that tamoxifen (mean difference, -22.31 [-25.97, -18.63], N = 2, n1 = 43, n2 = 39) and tamoxifen+ lithium or valproate (LIT/VAL) (-16.37 [-22.55, -10.25], N = 1, n1 = 20, n2 = 20) had the best and second-best clinical efficacy in adults with acute bipolar mania over the placebo. Furthermore, olanzapine, paliperidone, quetiapine, ziprasidone, risperidone, divalproex, and haloperidol were significantly better tolerated than placebo. Combination therapies of antipsychotics and LIT/VAL appeared to be more effective than their corresponding monotherapies. While pharmacotherapies were associated with specific common adverse events, we found no evidence of increased incidence of headache or depression events compared to the placebo. Overall, our NMAs provided important insights into the effectiveness, safety, and tolerability of pharmacological treatments for acute bipolar mania and can help guide treatment decisions for clinicians.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Huang W, He S, Liu M, et al. Comparative efficacy, safety, and tolerability of pharmacotherapies for acute mania in adults: a systematic review and network meta-analysis of randomized controlled trials. Mol Psychiatry. 2024. PMID: 39191865. doi:10.1038/s41380-024-02705-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。